SCHEDULE: ARS Pharma Secures $250M Debt Facility from RA Capital

ARS Pharmaceuticals, Inc. has entered into a credit agreement for up to $250 million in term loans with RA Capital affiliates and OMERS Administration Corporation to fund product development and general corporate purposes.

Summary

• ARS Pharmaceuticals, Inc. (the "Issuer") and its subsidiary, ARS Pharmaceuticals Operations, Inc. (the "Borrower"), secured a credit agreement for up to $250.0 million in term loans.
• The lenders include affiliates of RA Capital and OMERS Administration Corporation.
• The first tranche, Term A Loan, for $100.0 million was advanced on September 29, 2025.
• Proceeds will fund research, development, product commercialization, and general corporate purposes.
• The loans mature on the five-year anniversary of the Closing Date.
• The initial interest rate is 5.50% plus the greater of three-month forward-looking term SOFR or 3.00%, with potential reductions based on revenue milestones.
• Interest can be paid-in-kind (PIK) for the first two years (100%) and last three years (50%), increasing the applicable interest rate by 1.00% per annum for the PIK portion.
• The loans are guaranteed by the Company and secured by substantially all of its tangible and intangible assets, including intellectual property.
• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. collectively beneficially own 10,940,977 shares, representing 11.1% of the common stock.

Sentiment

Score: 7

Explanation: Securing a substantial debt facility of up to $250 million is a positive development, providing crucial capital for R&D and commercialization without immediate equity dilution. The involvement of reputable lenders like RA Capital and OMERS signals confidence. However, the high interest rate, asset-backed security, and restrictive covenants introduce significant financial obligations and risks, tempering the overall positive sentiment.

Positives

• Secured significant non-dilutive financing of up to $250.0 million.
• Initial $100.0 million Term A Loan provides immediate capital for operations.
• Funding is earmarked for critical R&D, product development, and commercialization activities.
• Flexibility with future tranches (Term B, C, D) allows access to capital as needed and upon achieving milestones.
• Option for paid-in-kind interest provides cash flow flexibility in early years.
• RA Capital, a significant existing shareholder, is also a lender, indicating continued confidence.

Negatives

• The debt is secured by substantially all of the company's assets, including intellectual property, which is a significant encumbrance.
• Future tranches are subject to conditions, including achieving $100.0 million in TTM net revenues for neffy for the Term C Loan, and lender consent for Term D.
• High interest rate (5.50% + SOFR/3.00% floor, plus 1.00% for PIK) indicates a higher risk profile from the lenders' perspective.
• Various fees (upfront, administration, repayment premium, exit fee) will increase the overall cost of borrowing.
• Negative covenants impose restrictions on the company's financial and operational flexibility (e.g., investments, additional debt, dividends, minimum liquidity).

Risks

• Failure to achieve the $100.0 million TTM net revenue milestone for neffy could prevent access to the Term C Loan.
• Inability to secure lender consent for the uncommitted Term D Loan could limit future funding.
• The company's assets, including critical intellectual property, are pledged as collateral, posing a risk in case of default.
• Breach of negative covenants (e.g., minimum liquidity threshold) could trigger an event of default.
• High interest burden, especially if PIK option is utilized, could lead to significant debt accumulation.
• Reliance on a single lender group (RA Capital affiliates, OMERS) for a substantial portion of financing.

Future Outlook

The company plans to use the term loan proceeds to fund ongoing research, development, and commercialization activities for its products, indicating a focus on advancing its pipeline and bringing products to market. Future access to additional tranches is contingent on achieving specific milestones, including revenue targets for neffy.

Industry Context

Securing significant debt financing is a common strategy for biotechnology and pharmaceutical companies, especially those in development or early commercialization stages, to fund capital-intensive R&D and market launch activities without immediate equity dilution. The involvement of specialized healthcare investors like RA Capital and large institutional investors like OMERS is typical for such deals, reflecting confidence in the company's pipeline and market potential, albeit with structured conditions and collateral.

Comparison to Industry Standards

• Debt facilities of this size (up to $250 million) are substantial for a company like ARS Pharmaceuticals, indicating significant investor confidence in its potential, particularly for its lead product neffy.
• The structure with multiple tranches, tied to milestones (e.g., $100 million TTM net revenues for neffy), is a standard practice in biotech debt financing, allowing lenders to de-risk their investment as the company progresses.
• The interest rate, including a SOFR-based component and a floor, along with a PIK option, is typical for growth-stage biotech companies that may not yet be cash-flow positive, reflecting the inherent risk but also providing flexibility.
• The requirement for collateral, including intellectual property, is also standard for venture debt or similar facilities in the life sciences sector, where IP is often the most valuable asset.

Related Party Transactions

• RA Capital Management, L.P. and its affiliates are both significant beneficial owners of ARS Pharmaceuticals' common stock (11.1%) and are also key lenders in the $250.0 million credit agreement.

Stakeholder Impact

• Shareholders: Avoids immediate equity dilution, but introduces significant debt and associated risks (e.g., asset pledges, covenants, potential default). The financing provides runway for product development, which could increase long-term value if successful.
• Employees: Provides continued funding for operations, potentially ensuring job security and progress on projects.
• Creditors (Lenders): Have a secured position on substantially all of the company's assets, including intellectual property, and benefit from a high interest rate and various fees.
• Customers: Potential for accelerated product development and commercialization, leading to new or improved products.

Next Steps

• Utilize the $100.0 million Term A Loan for research, development, product commercialization, and general corporate purposes.
• Potentially draw the $25.0 million Term B Loan between March 29, 2026, and September 29, 2026.
• Work towards achieving $100.0 million in TTM net revenues for neffy to qualify for the $25.0 million Term C Loan.
• Seek lender consent for the uncommitted Term D Loan of up to $100.0 million.
• Continue product development and commercialization activities.

Key Dates

Recommendation

While securing a substantial debt facility of up to $250 million is a positive for ARS Pharmaceuticals, providing crucial capital for R&D and commercialization without immediate equity dilution, the terms of the agreement warrant caution. The high interest rate, the pledge of substantially all company assets including intellectual property, and restrictive covenants introduce significant financial obligations and risks. The future tranches are contingent on performance milestones, particularly for neffy, adding uncertainty. Given the balance of necessary funding against the considerable debt burden and associated risks, a 'hold' recommendation is appropriate. Investors should monitor the company's progress on neffy's revenue milestones and overall financial health.

Keywords

ARS Pharmaceuticals, RA Capital, OMERS, Credit Agreement, Term Loans, Debt Financing, Biotechnology, Pharmaceuticals, Neffy, Product Development, Commercialization, SEC Filing, Schedule 13D/A